Iceland· IS-EU/1/19/1404/001-005
Rinvoq
A upadacitinib product containing upadacitinibum inn, registered in Iceland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Upadacitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AF03 (upadacitinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Upadacitinib · ATC L04AF03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of upadacitinib costs, country by country.
Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Upadacitinib · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$32.01
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Upadacitinibum INN
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Iceland (IS)
- ATC code
- L04AF03
- ATC class
- Upadacitinib
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean99642328 stk x1 pakkiISK 149477
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
407 interactions on record for upadacitinib.
Graded by severity as the source publishes them — 337 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Upadacitinib · interactions on record
407 records
- 337 severe
- 63 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Upadacitinib in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesRinvoqAbbVie Inc.
- SpainRINVOQ 15 MG COMPRIMIDOS DE LIBERACION PROLONGADAAbbvie Deutschland Gmbh & Co. Kg
- United KingdomRinvoq 15mg modified-release tabletsAbbVie Ltd
- NetherlandsRINVOQ 15 mg tabletten met verlengde afgifteAbbVie Deutschland GmbH & Co. KG
- CanadaRINVOQABBVIE CORPORATION
- PolandRinvoqAbbVie Deutschland GmbH & Co. KG
- SwedenRINVOQ 15 mg DepottablettAbbVie Deutschland GmbH & Co KG
- NorwayRinvoqAbbVie Deutschland GmbH & Co
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Rinvoq
- Liechtenstein · Rinvoq
- Norway · Rinvoq
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1bda4e3a-610c-41fb-b023-625082bb7027 GET /v1/drugs/1bda4e3a-610c-41fb-b023-625082bb7027?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Forðatafla",
"source": "lyfjastofnun",
"atc_raw": "L04AF03",
"marketed": true,
"strength": "15 mg",
"ma_number": "EU/1/19/1404/001-005",
"substance": "Upadacitinibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í gigtarlækningum, húðsjúkdómum, meltingarsjúkdómum og ónæmisfræði.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43815"
}See everything about upadacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.